HC Wainwright Issues Optimistic Estimate for MNPR Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at HC Wainwright increased their FY2027 earnings per share (EPS) estimates for Monopar Therapeutics in a research note issued on Wednesday, July 22nd. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.35) per share for the year, up from their previous forecast of ($1.37). HC Wainwright has a “Buy” rating and a $125.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2028 earnings at $0.91 EPS, FY2029 earnings at $2.41 EPS and FY2030 earnings at $6.61 EPS.

Several other equities analysts also recently issued reports on the stock. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday. BTIG Research increased their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a research report on Monday, March 30th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $112.08.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $109.87 on Friday. The company’s fifty day moving average price is $80.50 and its 200 day moving average price is $66.67. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $116.64. The firm has a market capitalization of $736.13 million, a P/E ratio of -57.83 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.41.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter worth $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares in the last quarter. Sei Investments Co. increased its stake in shares of Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after acquiring an additional 656 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth about $65,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Monopar Therapeutics during the fourth quarter worth about $86,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.